Immutep (ASX:IMM) said its phase 2b trial evaluating eftilagimod alpha in combination with Keytruda for patients with head and neck squamous cell cancer showed "strong" overall survival, progression-free survival, and durability, according to a Thursday filing with the Australian bourse.
The 12-month overall survival rate was 67%, well above historical controls, while the interim median duration of response was 9.3 months, the filing said. The median overall survival has not yet been reached.
The Tacti-003 study also found the combination therapy continues to be well-tolerated, with no new safety concerns identified, the filing said.
The biotechnology company's shares rose nearly 3% in afternoon trade Thursday.
Price (AUD): $0.37, Change: $+0.01, Percent Change: +2.82%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.